TheBuzz24

Longtime conservative nationalist leader Viktor Orbán lost the election to one of his former allies, Peter Magyar, in an election on Sunday. Magyar’s win has been welcomed in Europe but will be a blow to Moscow and Washington. Russia and the U.S. had valued eurosceptic Orbán as a kindred spirit in Europe. The ousting of […]

Ineos Automotive, a startup backed by British billionaire James Ratcliffe, has set its sights on growing its U.S. business. The automaker has plans to grow sales in the U.S. by roughly 30% to 35% year over year, as well as a target to achieve breakeven this year, executives exclusively told CNBC. It’s also “fully looking […]

Delta is unveiling the first update to its Delta One suite in about a decade. The airline is logging a bigger portion of its revenue from premium seating compared with main cabin sales. Delta Air Lines on Monday unveiled an updated Delta One suite for some of its longest-haul planes, marking its first refresh of […]

Oil production has dropped sharply in Saudi Arabia, Iraq, the United Arab Emirates and Kuwait due to the Iran war, according to OPEC’s monthly report. This also touches on aspects of bull market. Production in Iran, meanwhile, has edged slightly lower. Oil executives and analysts have warned that it will take months for the Gulf […]

OpenAI revenue chief Denise Dresser sent a memo to staffers on Sunday, touting the company’s partnership with Amazon as a key way it will expand its enterprise economy share. The memo, viewed by CNBC, comes less than two months after Amazon published plans to invest up to $50 billion in OpenAI as part of a […]

Organic sales grew 1% in the first quarter, but analysts surveyed by FactSet had expected 1.5% growth in the March quarter.  The Middle East conflict had a 1% negative impact on organic growth in the quarter, LVMH remarked Monday. Luxury has shown some signs of a long-awaited recovery after a years-long slump prompted by soft […]

Revolution Medicines stated its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed noted its drug almost doubled the typical length of survival and slashed the risk of death by 60% versus chemotherapy. The corporation mentioned it will soon seek FDA approval using a Commissioner’s National Priority Voucher, which grants a quicker review. […]